Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

Core Insights - Autolus Therapeutics plc is preparing to present five abstracts at the American Society of Hematology (ASH) Annual Meeting, highlighting the potential of its programmed T cell therapy, obe-cel, in treating severe and difficult-to-treat patient populations [1][2] Group 1: Clinical Data and Presentations - The upcoming ASH Annual Meeting will feature data supporting the long-term efficacy of obe-cel in hematological oncology and autoimmune diseases, with a focus on real-world experiences from the ROCCA consortium [2] - Abstract 302 will present initial findings from the CARLYSLE study, indicating a favorable safety profile and clinical benefits of obe-cel in patients with severe, refractory systemic lupus erythematosus [3] - Abstract 4429 will discuss how specific CAR product cell phenotypes correlate with clinical outcomes, revealing that a higher percentage of central memory cells in the drug product predicts better overall survival [4] - Preliminary findings from the Phase Ib/II CATULUS trial will be presented, showing a high overall response rate of 95% in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia [6] - Abstract 4060 will explore the persistence of CAR T-cells at month 3 as a predictor of long-term outcomes in adult patients with relapsed/refractory B-ALL [7] Group 2: Company Overview and Product Information - Autolus Therapeutics is an early commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases, utilizing proprietary T cell programming technologies [9] - AUCATZYL (obe-cel) is a CD19-directed CAR T cell therapy approved for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, designed to improve clinical activity and safety compared to existing therapies [10][11]